Insmed (NASDAQ: INSM) reported Q2 EPS of ($0.80), $0.09 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $58.79 million.

As of June 30, 2022, Insmed had cash and cash equivalents and marketable securities of $564.6 million. The Company\'s total operating expenses for the second quarter of 2022 were $153.5 million.

For earnings history and earnings-related data on Insmed (INSM) click here.